Evidence map›Paper›PMID 25612897›Full record

ArticleThe international journal of neuropsychopharmacology2015

Aberrant Monoaminergic System in Thyroid Hormone Receptor-β Deficient Mice as a Model of Attention-Deficit/Hyperactivity Disorder.

Masanori Ookubo, Miyuki Sadamatsu, Atsushi Yoshimura, Satoru Suzuki, Nobumasa Kato, Hideto Kojima, Naoto Yamada, Hirohiko Kanai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Treatment Preferences in Patients With Hypothyroidism.The Journal of clinical endocrinology and metabolism · 2025
    Pooled it
  2. Trial
  3. A study of the correlation between cognitive function and thyroid hormones in patients with Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  4. Article
  5. Article
  6. Local Thyroid Hormone Action in Brain Development.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Frontiers in behavioral neuroscience · 2022
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Masanori OokuboDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai).
Miyuki SadamatsuDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai).
Atsushi YoshimuraDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai).
Satoru SuzukiDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai).
Nobumasa KatoDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai).
Hideto KojimaDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai).
Naoto YamadaDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai).
Hirohiko KanaiDepartment of Psychiatry, Shiga University of Medical Science, Shiga, Japan (Drs Ookubo, Yoshimura, Yamada, and Kanai); Department of Psychiatry, Minakuchi Hospital, Shiga, Japan (Dr Ookubo); Department of Psychology and Psychiatry, Human Sciences, Kinjo Gakuin University, Aich, Japan (Dr Sadamatsu); Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima, Japan (Dr Suzuki); Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan (Dr Kato); Department of Molecular Genetics in Medicine, Shiga University of Medical Science, Shiga, Japan (Dr. Kojima); Department of Psychiatry, Japanese Red Cross Society Nagahama Hospital, Shiga, Japan (Dr. Kanai). h-kanai@nagahama.jrc.or.jp.
Showa University · JPFukushima Medical University · JPKinjo Gakuin University · JPSuzuki (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThyroid hormone receptors are divided into 2 functional types: TRα and TRβ. Thyroid hormone receptors play pivotal roles in the developing brain, and disruption of thyroid hormone receptors can produce permanent behavioral abnormality in animal models and humans.

methodsHere we examined behavioralchanges, regional monoamine metabolism, and expression of epigenetic modulatory proteins, including acetylated histone H3 and histone deacetylase, in the developing brain of TRα-disrupted (TRα (0/0) ) and TRβ-deficient (TRβ (-/-) ) mice. Tissue concentrations of dopamine, serotonin (5-hydroxytryptamine) and their metabolites in the mesocorticolimbic pathway were measured.

resultsTRβ (-/-) mice, a model of attention-deficit/hyperactivity disorder, showed significantly high exploratory activity and reduced habituation, whereas TRα (0/0) mice showed normal exploratory activity. The biochemical profiles of dopamine and 5-hydroxytryptamine showed significantly low dopamine metabolic rates in the caudate putamen and nucleus accumbens and overall low 5-hydroxytryptamine metabolic rates in TRβ (-/-) mice, but not in TRα (0/0) mice. Furthermore, the expression of acetylated histone H3 was low in the dorsal raphe of TRβ (-/-) mice, and histone deacetylase 2/3 proteins were widely increased in the mesolimbic system.

conclusionsThese findings suggest that TRβ deficiency causes dysfunction of the monoaminergic system, accompanied by epigenetic disruption during the brain maturation process.

Indexed as

Behavior, AnimalAnimalsAttention Deficit Disorder with HyperactivityBiogenic MonoaminesBrainDisease Models, AnimalDopamineDorsal Raphe NucleusExploratory BehaviorHabituation, PsychophysiologicHistone DeacetylasesHistonesLimbic SystemMaleMiceMice, Inbred C57BLBiogenic MonoaminesDopamineHistone DeacetylasesHistonesSerotoninThyroid Hormone Receptors betaADHDdopaminehistone deacetylasereward systemserotonin

Identifiers

PMID25612897
PMCPMC4540106
OpenAlexW2043019555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.